Ixabepilone

Alison Conlin; Monica Fornier; Clifford Hudis; Santwana Kar; Peter Kirkpatrick

doi:10.1038/nrd2469

Ixabepilone

Alison Conlin
, Monica Fornier
, Clifford Hudis
, Santwana Kar
, Peter Kirkpatrick

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.

Original language	English
Pages (from-to)	953-954
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	6
Issue number	12
DOIs	https://doi.org/10.1038/nrd2469
State	Published - Dec 2007

Access to Document

10.1038/nrd2469

Cite this

@article{bd3056f714444872abebc2cdc8b30858,

title = "Ixabepilone",

abstract = "Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.",

author = "Alison Conlin and Monica Fornier and Clifford Hudis and Santwana Kar and Peter Kirkpatrick",

year = "2007",

month = dec,

doi = "10.1038/nrd2469",

language = "English",

volume = "6",

pages = "953--954",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - Ixabepilone

AU - Conlin, Alison

AU - Fornier, Monica

AU - Hudis, Clifford

AU - Kar, Santwana

AU - Kirkpatrick, Peter

PY - 2007/12

Y1 - 2007/12

N2 - Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.

AB - Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.

UR - https://www.scopus.com/pages/publications/36749067772

U2 - 10.1038/nrd2469

DO - 10.1038/nrd2469

M3 - Article

AN - SCOPUS:36749067772

SN - 1474-1776

VL - 6

SP - 953

EP - 954

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 12

ER -

Ixabepilone

Abstract

Access to Document

Other files and links

Fingerprint

Cite this